The challenges of translating neuroprotective interventions with promising efficacy in animal studies into effective treatments for patients with stroke are well documented, with issues including ...
FreeOx Biotech, a clinical-stage biopharmaceutical company pioneering a novel drug class for Acute Ischemic Stroke (AIS), announced significant progress in 2024, driven by cutting-edge clinical ...
Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...
Stroke experts from UCSF Health presented new research and clinical findings at the annual the American Stroke Association’s International Stroke Conference (ISC25), the world’s premier meeting ...
Removing a blood clot from a large brain artery, then injecting the clot-dissolving drug tenecteplase into the artery resulted in stroke survivors being more likely to have better function 90 days ...
The clot-dissolving medication, alteplase, improved stroke patients' recovery by more than 50% when given up to 24 hours after the beginning of an ischemic stroke, according to preliminary ...
Removing a blood clot from a large brain artery, then injecting the clot-dissolving drug tenecteplase into the artery ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback